Welcome to our dedicated page for GoodRx Holdings news (Ticker: GDRX), a resource for investors and traders seeking the latest updates and insights on GoodRx Holdings stock.
GoodRx Holdings, Inc. (Symbol: GDRX) is a leading consumer-focused digital healthcare platform committed to reducing the cost of healthcare in the United States. The company operates a price comparison platform that provides consumers with current, geographically relevant pricing for prescription medications. GoodRx gathers prices from multiple sources, offering powerful savings tips, valuable discounts, and negotiable price codes for prescriptions at virtually every pharmacy across the US.
GoodRx serves millions of Americans each month, including thousands of physicians who use the platform to help their patients. To date, the company has saved users over $3 billion on their prescription drug costs. Despite this success, GoodRx continues to work toward making prescriptions affordable for all Americans.
The company's core revenue stream comes from pharmacy benefit managers (PBMs), who manage formularies and prescription transactions. GoodRx also offers additional healthcare products and services such as pharma manufacturer solutions, subscription plans, and telehealth services. Their platform extends beyond individual consumers to include solutions for health plans, payors, and PBMs through an easy-to-use website and mobile app experience known as GoodRx for Benefits.
As GoodRx continues to innovate and expand its offerings, it remains dedicated to its mission of lowering healthcare costs and making essential medications accessible to everyone in the US. Stay updated with the latest news and developments from GoodRx to see how they are transforming the healthcare landscape.
GoodRx (Nasdaq: GDRX) has appointed Simon Patterson to its Board of Directors. Patterson, who leads EMEA operations for Silver Lake, a technology investment firm, brings extensive experience in tech, strategy, and management. He has held board positions at companies like Dell Technologies and Skype. Patterson's expertise is expected to assist GoodRx in scaling its business and making prescription medications more affordable. He will also join the Board's Nominating and Corporate Governance Committee.
GoodRx (Nasdaq: GDRX) has been named to the 2024 TIME100 Most Influential Companies list for the second time. Recognized for its innovative strategies to reduce prescription medication costs, GoodRx has saved consumers around $15 billion in 2023 alone. The company's efforts include integrating savings with insurance benefits, partnering with pharmacies, and collaborating with pharmaceutical manufacturers. Since its founding in 2011, GoodRx has facilitated the purchase of 184 million prescriptions, potentially saving the healthcare system over $5 billion in preventable ER visits and hospitalizations.
GoodRx, a leader in prescription savings, has announced discounts of up to 43% on fertility treatments in 2023. Americans saved over $6 million using GoodRx for fertility medications. The initiative covers generic and brand-name medications used in IVF, helping to manage the high costs of fertility treatments, which can range from $15,000 to $30,000 per cycle. Highlights include significant savings on medications such as Fyremadel, Ganirelix, Leuprolide, Clomid, and Letrozole. GoodRx also offers a Fertility Hub for educational resources and additional savings. The discounts aim to alleviate financial burdens and assist families in their reproductive journeys.
GoodRx (Nasdaq: GDRX) has entered a new direct contracting agreement with The Kroger Co. to offer enhanced prescription savings at over 2,200 Kroger pharmacy locations nationwide.
Starting June 1, 2024, patients using a GoodRx coupon can expect almost 50% more savings on most generic medications.
This partnership aims to support Kroger's business objectives and improve patients' access to affordable prescriptions.
GoodRx will discuss this agreement during its Investor Day on May 15 at 9 a.m. ET.
GoodRx Holdings, Inc. reported financial results for the first quarter of 2024. Revenue increased by 8% to $197.9 million, with a net loss of $1.0 million. Adjusted EBITDA was $62.8 million. The company focuses on capital allocation, share repurchases, and M&A. GoodRx anticipates revenue growth for the second quarter and full year 2024.
FAQ
What is the current stock price of GoodRx Holdings (GDRX)?
What is the market cap of GoodRx Holdings (GDRX)?
What does GoodRx Holdings, Inc. do?
How does GoodRx save money on prescriptions?
Who benefits from using GoodRx?
How much has GoodRx saved Americans so far?
What additional services does GoodRx offer?
How does GoodRx generate revenue?
What is GoodRx for Benefits?
Is GoodRx available as a mobile app?
Why should I use GoodRx if I already have insurance?
Where can I learn more about GoodRx?
